• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Rev Med Virol . The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19: A systematic review and meta-analysis

tetano

Editor, Senior Moderator
Rev Med Virol


. 2021 Oct 13;e2304.
doi: 10.1002/rmv.2304. Online ahead of print.
The prevalence, predictors and outcomes of acute liver injury among patients with COVID-19: A systematic review and meta-analysis


Harapan Harapan[SUP] 1 2 3 [/SUP], Jonny Karunia Fajar[SUP] 4 [/SUP], Supriono Supriono[SUP] 5 [/SUP], Gatot Soegiarto[SUP] 6 [/SUP], Laksmi Wulandari[SUP] 7 [/SUP], Fiha Seratin[SUP] 8 [/SUP], Nyoman Gede Prayudi[SUP] 9 [/SUP], Dara Puspita Dewi[SUP] 10 [/SUP], Maria Theresia Monica Elsina[SUP] 11 [/SUP], Lasarus Atamou[SUP] 11 [/SUP], Sinta Wiranata[SUP] 12 [/SUP], Dhito Pemi Aprianto[SUP] 10 [/SUP], Erlin Friska[SUP] 13 [/SUP], D Fitria Sari Firdaus[SUP] 13 [/SUP], Makdum Alaidin[SUP] 14 [/SUP], Firdha Aprillia Wardhani[SUP] 15 [/SUP], Milda Husnah[SUP] 16 [/SUP], Nurdina Wahyu Hidayati[SUP] 15 [/SUP], Yeni Hendriyanti[SUP] 15 [/SUP], Kristia Wardani[SUP] 4 [/SUP], Arde Evatta[SUP] 4 [/SUP], Reizal Audi Manugan[SUP] 4 [/SUP], Wiryawan Pradipto[SUP] 4 [/SUP], Ade Rahmawati[SUP] 4 [/SUP], Fredo Tamara[SUP] 4 [/SUP], Aditya Indra Mahendra[SUP] 4 [/SUP], Firzan Nainu[SUP] 17 [/SUP], Budi Santoso[SUP] 18 [/SUP], Chandra Adi Irawan Primasatya[SUP] 19 [/SUP], Nindy Tjionganata[SUP] 20 [/SUP], Hendarto Arif Budiman[SUP] 19 [/SUP]



Affiliations

Abstract

The data on the predictors and prognosis of acute liver injury (ALI) among patients in coronavirus disease 2019 (COVID-19) patients are limited. The aim of this study was to determine the prevalence, predictors and outcomes of ALI among patients with COVID-19. A systematic review was conducted up to 10 June 2021. The relevant papers were searched from PubMed, Embase, Cochrane and Web of Science, and the data were analysed using a Z test. A total of 1331 papers were identified and 16 papers consisting of 1254 COVID-19 with ALI and 4999 COVID-19 without ALI were analysed. The cumulative prevalence of ALI among patients with COVID-19 was 22.8%. Male and having low lymphocyte levels were more likely to be associated with ALI compared with female and having higher lymphocyte level, odds ratio (OR): 2.70; 95% confidence interval (CI): 2.03, 3.60 and mean difference (MD) -125; 95% CI: -207, -43, respectively. COVID-19 patients with ALI had higher risk of developing severe COVID-19 compared with those without ALI (OR: 3.61; 95% CI: 2.60, 5.02). Our findings may serve as the additional evaluation for the management of ALI in COVID-19 patients.

Keywords: COVID-19; acute liver injury; outcome; predictor; prevalence.
 
Back
Top Bottom